stockportfolio.pro
Collegium Pharmaceutical, Inc. (COLL)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Collegium Pharmaceutical, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.71M | $28.48M | $280.41M | $296.70M | $310.02M | $276.87M | $463.93M | $566.77M | $631.45M | $780.57M |
| Gross profit | $1.50M | $25.88M | $114.74M | $103.04M | $179.84M | $150.62M | $209.49M | $326.17M | $377.34M | $463.26M |
| Net income | $-94.18M | $-74.86M | $-39.13M | $-22.72M | $26.75M | $71.52M | $-25.00M | $48.16M | $69.19M | $62.87M |
| Net margin | -5504.1% | -262.9% | -14.0% | -7.7% | 8.6% | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
Source: Collegium Pharmaceutical, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Collegium Pharmaceutical, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track COLL in your portfolio →
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. — frequently asked questions
What is Collegium Pharmaceutical, Inc.'s revenue?
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $780.57M for fiscal year 2025, up 23.6% from the prior year, according to its SEC filings.
Is Collegium Pharmaceutical, Inc. profitable?
Yes. COLL earned net income of $62.87M in fiscal 2025, a net margin of 8.1%.
What is COLL's P/E ratio?
Collegium Pharmaceutical, Inc. trades at a price-to-earnings ratio of about 16.8 based on the latest data in our nightly-refreshed cache.
How fast is Collegium Pharmaceutical, Inc. growing?
COLL's revenue grew at roughly 20.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Collegium Pharmaceutical, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.